FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366236443> ?p ?o ?g. }

• W4366236443 endingPage "e45263" @default.
• W4366236443 startingPage "e45263" @default.
• W4366236443 abstract "The World Health Organization recently described sudden sensorineural hearing loss (SSNHL) as a possible adverse effect of COVID-19 vaccines. Recent discordant pharmacoepidemiologic studies invite robust clinical investigations of SSNHL after COVID-19 messenger RNA (mRNA) vaccines. This postmarketing surveillance study, overseen by French public health authorities, is the first to clinically document postvaccination SSNHL and examine the role of potential risk factors.This nationwide study aimed to assess the relationship between SSNHL and exposure to mRNA COVID-19 vaccines and estimate the reporting rate (Rr) of SSNHL after mRNA vaccination per 1 million doses (primary outcome).We performed a retrospective review of all suspected cases of SSNHL after mRNA COVID-19 vaccination spontaneously reported in France between January 2021 and February 2022 based on a comprehensive medical evaluation, including the evaluation of patient medical history, side and range of hearing loss, and hearing recovery outcomes after a minimum period of 3 months. The quantification of hearing loss and assessment of hearing recovery outcomes were performed according to a grading system modified from the Siegel criteria. A cutoff of 21 days was used for the delay onset of SSNHL. The primary outcome was estimated using the total number of doses of each vaccine administered during the study period in France as the denominator.From 400 extracted cases for tozinameran and elasomeran, 345 (86.3%) spontaneous reports were selected. After reviewing complementary data, 49.6% (171/345) of documented cases of SSNHL were identified. Of these, 83% (142/171) of SSNHL cases occurred after tozinameran vaccination: Rr=1.45/1,000,000 injections; no difference for the rank of injections; complete recovery in 22.5% (32/142) of cases; median delay onset before day 21=4 days (median age 51, IQR 13-83 years); and no effects of sex. A total of 16.9% (29/171) of SSNHL cases occurred after elasomeran vaccination: Rr=1.67/1,000,000 injections; rank effect in favor of the first injection (P=.03); complete recovery in 24% (7/29) of cases; median delay onset before day 21=8 days (median age 47, IQR 33-81 years); and no effects of sex. Autoimmune, cardiovascular, or audiovestibular risk factors were present in approximately 29.8% (51/171) of the cases. SSNHL was more often unilateral than bilateral for both mRNA vaccines (P<.001 for tozinameran; P<.003 for elasomeran). There were 13.5% (23/142) of cases of profound hearing loss, among which 74% (17/23) did not recover a serviceable ear. A positive rechallenge was documented for 8 cases.SSNHL after COVID-19 mRNA vaccines are very rare adverse events that do not call into question the benefits of mRNA vaccines but deserve to be known given the potentially disabling impact of sudden deafness. Therefore, it is essential to properly characterize postinjection SSNHL, especially in the case of a positive rechallenge, to provide appropriate individualized recommendations." @default.
• W4366236443 created "2023-04-20" @default.
• W4366236443 creator A5008225828 @default.
• W4366236443 creator A5012427890 @default.
• W4366236443 creator A5016427260 @default.
• W4366236443 creator A5019502231 @default.
• W4366236443 creator A5021430487 @default.
• W4366236443 creator A5030245594 @default.
• W4366236443 creator A5058602661 @default.
• W4366236443 creator A5072211974 @default.
• W4366236443 creator A5079618593 @default.
• W4366236443 creator A5086672182 @default.
• W4366236443 creator A5087751306 @default.
• W4366236443 date "2023-07-14" @default.
• W4366236443 modified "2023-09-30" @default.
• W4366236443 title "Safety Signal Generation for Sudden Sensorineural Hearing Loss Following Messenger RNA COVID-19 Vaccination: Postmarketing Surveillance Using the French Pharmacovigilance Spontaneous Reporting Database" @default.
• W4366236443 cites W102010054 @default.
• W4366236443 cites W1966238900 @default.
• W4366236443 cites W1977356526 @default.
• W4366236443 cites W2004012066 @default.
• W4366236443 cites W2069192158 @default.
• W4366236443 cites W2112624063 @default.
• W4366236443 cites W2137588072 @default.
• W4366236443 cites W2171428938 @default.
• W4366236443 cites W2467440030 @default.
• W4366236443 cites W2484244812 @default.
• W4366236443 cites W2809140339 @default.
• W4366236443 cites W2899417061 @default.
• W4366236443 cites W2965014570 @default.
• W4366236443 cites W2966563382 @default.
• W4366236443 cites W3013767414 @default.
• W4366236443 cites W3016103572 @default.
• W4366236443 cites W3017125154 @default.
• W4366236443 cites W3021992735 @default.
• W4366236443 cites W3022858319 @default.
• W4366236443 cites W3033360958 @default.
• W4366236443 cites W3033768958 @default.
• W4366236443 cites W3034545674 @default.
• W4366236443 cites W3045538490 @default.
• W4366236443 cites W3047457172 @default.
• W4366236443 cites W3047556506 @default.
• W4366236443 cites W3047892366 @default.
• W4366236443 cites W3083084485 @default.
• W4366236443 cites W3086601211 @default.
• W4366236443 cites W3089581979 @default.
• W4366236443 cites W3092307429 @default.
• W4366236443 cites W3092441382 @default.
• W4366236443 cites W3129663861 @default.
• W4366236443 cites W3137908755 @default.
• W4366236443 cites W3153239010 @default.
• W4366236443 cites W3157383433 @default.
• W4366236443 cites W3158285812 @default.
• W4366236443 cites W3161416590 @default.
• W4366236443 cites W3176269245 @default.
• W4366236443 cites W3180936776 @default.
• W4366236443 cites W3181875401 @default.
• W4366236443 cites W3195586393 @default.
• W4366236443 cites W3200853307 @default.
• W4366236443 cites W3205306418 @default.
• W4366236443 cites W3214938573 @default.
• W4366236443 cites W343259323 @default.
• W4366236443 cites W4210575617 @default.
• W4366236443 cites W4213018148 @default.
• W4366236443 cites W4213419757 @default.
• W4366236443 cites W4213441655 @default.
• W4366236443 cites W4213443697 @default.
• W4366236443 cites W4224244387 @default.
• W4366236443 cites W4225128211 @default.
• W4366236443 cites W4229017224 @default.
• W4366236443 cites W4233958921 @default.
• W4366236443 cites W4281717376 @default.
• W4366236443 cites W4281998594 @default.
• W4366236443 cites W4282942928 @default.
• W4366236443 cites W4283514019 @default.
• W4366236443 cites W4311590219 @default.
• W4366236443 cites W4320726275 @default.
• W4366236443 cites W4324340216 @default.
• W4366236443 doi "https://doi.org/10.2196/45263" @default.
• W4366236443 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37071555" @default.
• W4366236443 hasPublicationYear "2023" @default.
• W4366236443 type Work @default.
• W4366236443 citedByCount "0" @default.
• W4366236443 crossrefType "journal-article" @default.
• W4366236443 hasAuthorship W4366236443A5008225828 @default.
• W4366236443 hasAuthorship W4366236443A5012427890 @default.
• W4366236443 hasAuthorship W4366236443A5016427260 @default.
• W4366236443 hasAuthorship W4366236443A5019502231 @default.
• W4366236443 hasAuthorship W4366236443A5021430487 @default.
• W4366236443 hasAuthorship W4366236443A5030245594 @default.
• W4366236443 hasAuthorship W4366236443A5058602661 @default.
• W4366236443 hasAuthorship W4366236443A5072211974 @default.
• W4366236443 hasAuthorship W4366236443A5079618593 @default.
• W4366236443 hasAuthorship W4366236443A5086672182 @default.
• W4366236443 hasAuthorship W4366236443A5087751306 @default.
• W4366236443 hasBestOaLocation W43662364431 @default.
• W4366236443 hasConcept C126322002 @default.
• W4366236443 hasConcept C187212893 @default.
• W4366236443 hasConcept C194828623 @default.

• next